Figure 3 from Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Year: 2024
Type: other
Abstract: PFS according to mutation and molecular expression subgroups. Kaplan–Meier estimates of PFS in patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months who, at screening, had the presence of (A) PIK3CA-mut (n = 62; 39%); (B) PIK3CA wild-type (n = 97; 61%); (C) TP53-mut (n = 61; 38%); (D) TP53 wild-type (n = 97; 61%); (E) HER2-low expression (n = 77; 48%); (F) HER2-zero expression (n = 69; 43%); (G) ESR1D538G-mutated tumors (n = 97; 61%); or (H) ESR1Y537S/N-mutated tumors (n = 92; 58%). aIncludes the following PIK3CA-mut: E545K, H1047R, and E542K among others. bData not available for all patients. cHER2-low expression defined as IHC score of 1+ or 2+ with no amplification by ISH.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403043250